Micro Aftermath Archived

Abbott Laboratories bullish thesis on ABT

Activity declining — narrative losing relevance.

Score 0.3

Velocity ▲ 0.0

Articles 13

Sources 2

Top Movers

Ticker	Sector	Change
MSFT	Technology	+38.6%
ABT	Health Care	-0.5%

Sentiment Timeline

Sector Performance

Stock Performance

Event Timeline

May 07, 2026 Abbott Stock Is Trading at 52-Week Lows but Insiders Are Gobbling Up … Bullish

May 03, 2026 This Dividend King's Yield Hasn't Been This High in a Decade. Is … Bullish

May 02, 2026 Abbott Laboratories (ABT) Receives FDA Clearance and CE Mark for Next-Generation Ultreon™ … Bullish

May 01, 2026 Here’s Why Polen Focus Growth Exited Abbott Laboratories (ABT) in Q1 Bearish

Apr 26, 2026 Daiwa Downgrades Abbott Laboratories (ABT), Sees Limited Upside Bearish

Apr 19, 2026 Why Is Abbott Stock Trending Lower? Bearish

Apr 16, 2026 Abbott Laboratories Stock Drops 4% Over Decline In Q1 Earnings Bearish

Apr 14, 2026 Jim Cramer Says Abbot Is “Going to Have to Give Us a … Neutral

Mar 27, 2026 Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program Bullish

Mar 26, 2026 Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences Bullish

Mar 21, 2026 Is Abbott Laboratories (ABT) A Good Stock To Buy Now? Neutral

Abbott Stock Is Trading at 52-Week Lows but Insiders Are Gobbling Up Shares of This … Yahoo Finance · May 07, 2026 Mixed This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy? Nasdaq · May 03, 2026 Mixed Abbott Earnings Preview: What to Expect Yahoo Finance · Mar 26, 2026 Mixed Is Abbott Laboratories (ABT) A Good Stock To Buy Now? Yahoo Finance · Mar 21, 2026 Mixed

Top Movers

Ticker	Sector	Change
MSFT	Technology	+38.6%
ABT	Health Care	-0.5%

🤖 AI Overview

What happened: Abbott Laboratories (ABT) saw mixed sentiment in recent weeks. Jim Cramer expressed caution, awaiting reasons for ABT to rise. Wedbush, however, maintained a bullish stance on BDTX, a company ABT acquired (Exact Sciences). ABT's Ultreon™ 3.0 software received FDA clearance and CE Mark. Polen Capital exited ABT in Q1, and Daiwa downgraded ABT to neutral. ABT's stock dropped 26% over five months, with a 4% decline in Q1 earnings.

Market impact: The mixed sentiment around ABT affected the healthcare sector, particularly medical devices and diagnostics. The acquisition of Exact Sciences positioned ABT as a leader in cancer screening. The software clearance expanded ABT's product offerings. However, concerns about near-term risks and earnings declines led to a reassessment of ABT's valuation, driving its stock price down.

What to watch next: Abbott's Q2 earnings on May 4 will provide insights into the company's performance post-acquisition and software clearance. The market will also watch for any further analyst revisions to ABT's price target following Daiwa's downgrade. Additionally, any updates on ABT's pipeline and growth strategies will be crucial in determining the narrative's evolution.

AI Overview as of May 02, 2026

Timeline

First SeenMar 21, 2026

Last UpdatedMar 21, 2026

Abbott Laboratories bullish thesis on ABT

Top Movers

Sentiment Timeline

Sector Performance

Stock Performance

Event Timeline

Related Articles